TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Daniel M. MICHAELSON

Serial No.:

09/847,586

Filed:

May 3, 2001

For:

Peptides and Substances, Methods And

Devices Using Same For Diagnosing And

Treating Neurodegenerative Disorders

Examiner:

Group Art Unit: 1653

Attorney

Ş

00:00:00:00:00

§

Docket: 01/21573

ELECTION

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

This is in response to the United States Patent and Trademark Office Restriction Action mailed November 3, 2003, which response is being made on or before December 3, 2003.

Applicants hereby elect Group I, namely Claims 1-22, 55-64 and 115-142, drawn to a method of diagnosing disease by immunoreacting a serum sample with peptide epitopes and/or peptides bound to a solid support.

Furthermore, with respect to the species selection, Applicants hereby select from:

Specie A: Endogenous protein: NF-H.

Specie B: Type of epitope: continuous.

Specie C: Sequence ID No.: 77.

Specie D: Neurodegenerative/Ischemic Disorder: Alzheimer's Disease.

Specie E: Phospho amino acid: phosphoserine.

It is believed that Claims 1-3, 5-22, 55-64, 115-122 and 124-142 are readable on the elected species.

Applicants reserve the right to file, at a later date, additional divisional applications claiming priority from the present application which are directed to any one or more of the non-elected Groups.

Respectfully submitted,

Sol Sheinbein

Registration No. 25,457

Date: December 1, 2003